{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:10:35Z","timestamp":1769083835960,"version":"3.49.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The authors are thankful to the Deanship of Graduate Studies and Scientific Research at University of Bisha for supporting this work through the Fast-Track Research Support Program."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sepsis is a leading cause of morbidity and mortality in intensive care units, characterized by a dysregulated host response to infection. Recent evidence suggests fluoxetine, a selective serotonin reuptake inhibitor, may exert immunometabolic effects beneficial in sepsis. The aim of this study is to evaluate the effect of fluoxetine on vasopressor duration, organ dysfunction, inflammatory markers, and mortality in adult patients with severe sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this single-center, randomized, double-blind, placebo-controlled trial conducted at Ain Shams University Hospitals (December 2024\u2013June 2025), 46 patients with severe sepsis were randomized 1:1 to receive either fluoxetine (40\u2009mg\/day) or placebo in addition to standard sepsis care. The primary outcome was vasopressor duration. Secondary outcomes included Sequential Organ Failure Assessment (SOFA) scores, inflammatory biomarkers (CRP, TNF-\u03b1, IL-1, procalcitonin), lactate levels, ICU length of stay, and 28-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fluoxetine significantly reduced vasopressor duration (6.2\u2009\u00b1\u20090.4 vs. 7.9\u2009\u00b1\u20090.8 days; p\u2009&lt;\u20090.001), ICU stay (15.9\u2009\u00b1\u20091.6 vs. 17.1\u2009\u00b1\u20091.1 days; p\u2009=\u20090.005), and inflammatory markers by day 7, including TNF-\u03b1, IL-1, CRP, and procalcitonin (all p\u2009&lt;\u20090.05). SOFA and APACHE II scores were also lower in the fluoxetine group on days 7 and 10. No significant difference in 28-day mortality was observed (8.7% vs. 17.4%; p\u2009=\u20090.381).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fluoxetine as adjunctive therapy in severe sepsis may reduce vasopressor dependence, attenuate inflammation, and shorten ICU stay without increasing adverse effects. Its mortality benefit remains uncertain and warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340669","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:30:37Z","timestamp":1769020237000},"page":"e0340669","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of fluoxetine on organ dysfunction and mortality in severe sepsis"],"prefix":"10.1371","volume":"21","author":[{"given":"Islam Abdelaal Abdelmouty","family":"Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farouk Kamal","family":"Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A. Wareth","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-9429","authenticated-orcid":true,"given":"Lobna A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-7096","authenticated-orcid":true,"given":"Ahmed S.","family":"Doghish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr Sobhy","family":"Abdel Kway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"8","key":"pone.0340669.ref001","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"M Singer","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"pone.0340669.ref002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00134-017-5016-5","article-title":"Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock","volume":"44","author":"F Lamontagne","year":"2018","journal-title":"Intensive Care Med"},{"issue":"1","key":"pone.0340669.ref003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1465-9921-8-35","article-title":"Anti-inflammatory properties of desipramine and fluoxetine","volume":"8","author":"C Roumestan","year":"2007","journal-title":"Respir Res"},{"issue":"4","key":"pone.0340669.ref004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/1570159X12666140828221720","article-title":"Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects","volume":"12","author":"L Peng","year":"2014","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"pone.0340669.ref005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00005-019-00543-8","article-title":"The influence of antidepressants on the immune system","volume":"67","author":"\u0141P Sza\u0142ach","year":"2019","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"pone.0340669.ref006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12974-024-03312-3","article-title":"The immunological perspective of major depressive disorder: unveiling the interactions between central and peripheral immune mechanisms","volume":"22","author":"W Jiao","year":"2025","journal-title":"J Neuroinflammation"},{"issue":"7","key":"pone.0340669.ref007","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu4034","article-title":"Fluoxetine promotes IL-10-dependent metabolic defenses to protect from sepsis-induced lethality","volume":"11","author":"RM Gallant","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"pone.0340669.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"G Reis","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"7","key":"pone.0340669.ref009","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00134-018-5197-6","article-title":"Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis","volume":"44","author":"SL Ryg\u00e5rd","year":"2018","journal-title":"Intensive Care Med"},{"issue":"4","key":"pone.0340669.ref010","article-title":"Sepsis therapies: learning from 30 years of failure of translational research to propose new leads","volume":"12","author":"J-M Cavaillon","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"23","key":"pone.0340669.ref011","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group","volume":"271","author":"Jr Fisher CJ","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"pone.0340669.ref012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph18010104","article-title":"Targeting cytokine-mediated inflammation in brain disorders: developing new treatment strategies","volume":"18","author":"R Mallick","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"pone.0340669.ref013","doi-asserted-by":"crossref","DOI":"10.1136\/tsaco-2024-001733","article-title":"Unpacking the sepsis controversy","volume":"10","author":"J Alverdy","year":"2025","journal-title":"Trauma Surg Acute Care Open"},{"issue":"12","key":"pone.0340669.ref014","article-title":"Early versus late initiation of hydrocortisone in patients with septic shock: a prospective study","volume":"15","author":"Sr Alsulami M","year":"2023","journal-title":"Cureus"},{"key":"pone.0340669.ref015","doi-asserted-by":"crossref","first-page":"1340179","DOI":"10.3389\/fpsyt.2025.1340179","article-title":"Could antidepressants increase mood and immunity at the same time?","volume":"16","author":"F Lavergne","year":"2025","journal-title":"Front Psychiatry"},{"issue":"1","key":"pone.0340669.ref016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biomedicines10010056","article-title":"Off-target effects of antidepressants on vascular function and structure","volume":"10","author":"A Dimoula","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"pone.0340669.ref017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00134-016-4666-z","article-title":"Monitoring dynamic arterial elastance as a means of decreasing the duration of norepinephrine treatment in vasoplegic syndrome following cardiac surgery: a prospective, randomized trial","volume":"43","author":"P-G Guinot","year":"2017","journal-title":"Intensive Care Med"},{"issue":"8","key":"pone.0340669.ref018","doi-asserted-by":"crossref","first-page":"2025249","DOI":"10.31893\/multirev.2025249","article-title":"Evaluating the impact of early vs. late vasopressor use on outcomes in sepsis patients: a systematic review","volume":"8","author":"M Nelakuditi","year":"2025","journal-title":"Multidiscip Rev"},{"issue":"4","key":"pone.0340669.ref019","doi-asserted-by":"crossref","first-page":"100178","DOI":"10.1016\/j.chstcc.2025.100178","article-title":"Protocol and statistical analysis plan for the vasopressin for septic shock pragmatic (VASSPR) cluster-crossover randomized trial","volume":"3","author":"ID Peltan","year":"2025","journal-title":"CHEST Critical Care"},{"issue":"9","key":"pone.0340669.ref020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"B Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0340669.ref021","article-title":"Study on assessing serum lactate as an early prognostic determinant in sepsis outcome","volume":"16","author":"P Tejaswini","year":"2024","journal-title":"Cureus"},{"key":"pone.0340669.ref022","article-title":"Fluoxetine promotes immunometabolic defenses to mediate host-pathogen cooperation during sepsis","author":"RM Gallant","year":"2023","journal-title":"bioRxiv"},{"key":"pone.0340669.ref023","doi-asserted-by":"crossref","first-page":"165974","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view","volume":"2013","author":"W Schulte","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"9","key":"pone.0340669.ref024","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study","volume":"26","author":"N Hoertel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"478","key":"pone.0340669.ref025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"DA Rosen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"pone.0340669.ref026","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.intimp.2015.02.029","article-title":"Paroxetine differentially modulates LPS-induced TNF\u03b1 and IL-6 production in mouse macrophages","volume":"25","author":"H Durairaj","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"pone.0340669.ref027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbi.2011.12.011","article-title":"A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia","volume":"26","author":"RJ Tynan","year":"2012","journal-title":"Brain Behav Immun"},{"key":"pone.0340669.ref028","doi-asserted-by":"crossref","first-page":"111848","DOI":"10.1016\/j.biopha.2021.111848","article-title":"Fluoxetine ameliorates high-fat diet-induced metabolic abnormalities partially via reduced adipose triglyceride lipase-mediated adipocyte lipolysis","volume":"141","author":"Y-J Chiu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"pone.0340669.ref029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mce.2016.01.009","article-title":"Metabolic effect of fluvoxamine in mouse peripheral tissues","volume":"424","author":"S Rozenblit-Susan","year":"2016","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"pone.0340669.ref030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/aps.2017.207","article-title":"Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression","volume":"39","author":"S-J Pan","year":"2018","journal-title":"Acta Pharmacol Sin"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:30:41Z","timestamp":1769020241000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340669"}},"subtitle":[],"editor":[{"given":"Sungho","family":"Maeng","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340669","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}